<DOC>
	<DOCNO>NCT01574898</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetic profile nicotine follow single oral administration three new nicotine lozenge formulation ( V0474 ) comparison two reference product . The clinical biological safety V0474 lozenge acceptability also assess .</brief_summary>
	<brief_title>Pilot Pharmacokinetic Study New Nicotine Lozenge Formulations</brief_title>
	<detailed_description />
	<mesh_term>Nicotine</mesh_term>
	<criteria>Healthy male subject age 18 45 year ( inclusive ) Current smoker &lt; = 10 cigarettes/day Fagerstr√∂m score &lt; = 5 Absence clinically significant abnormal find physical , ECG , biological examination Investigator 's opinion Presence significant medical finding significant history ( particular cardiovascular disease , severe renal hepatic insufficiency , current gastric duodenal ulcer oesophagitis ) may impact safety , interpretation result and/or participation subject study accord opinion investigator Current recurrent buccal lesion</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Smoking cessation</keyword>
	<keyword>Nicotine</keyword>
	<keyword>Tobacco Use Disorder</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>